Displaying 1281 - 1300 of 1535
Resolving Anticompetitive Concerns, FTC Clears $16 Billion Acquisition of Immunex Corp. By Amgen Inc.
Administrative Law Judge Dismisses FTC Allegations of Anticompetitive Conduct by Schering-plough and Upsher-Smith
Generic Drug Entry Prior to Patent Expiration: An FTC Study
Announced Action for June 4, 2002
Obstetrics and Gynecology Medical Corporation of Napa Valley, a corporation et al.
A doctors’ group consisting of nearly every obstetrician and gynecologist with active medical staff privileges at the two general acute care hospitals in Napa County, California settled charges that they restrained price and other competition by engaging in illegal agreements to fix fees and other terms of dealing with health care insurance plans. According to the complaint issued with the consent order, the doctors refused to deal with the third party payers except on collectively determined terms. The consent order not only prevents the doctors from engaging in similar practices in the future but also requires the dissolution of the group.
Two Denver-area Physician Groups Agree To Settle FTC Charges of Fixing Fees
Physician Integrated Services of Denver, Inc., Michael J. Guese, M.D., and Marcia L. Brauchler
Aurora Associated Primary Care Physicians, L.L.C., Richard A. Patt, M.D., Gary L. Gaede, M.D., and Marcia L. Brauchler
Prepared Statement of the Federal Trade Commission On Pharmaceutical Industry
Biovail Corporation
The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book” for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.
Wrongful "Orange Book" Listing Raises Red Flag with FTC; Leads to Consent Order with Biovail Corp. Concerning its Drug Tiazac
The Antitrust Implications of "Clinical Integration:" An Analysis of FTC Staff's Advisory Opinion to MedSouth
Napa Valley OB/GYN Group Settles FTC Antitrust Charges
FTC Staff Opposes Alaska Physicians' Health Plan Legislation:
Staff Advisory Opinion:
FTC Agreement with American Home Products Corp. Would Protect Consumers from Anticompetitive Practices
Roche Holding Ltd, In the Matter of
Roche agreed to divest, certain assets in the U.S. and Canada to settle antitrust concerns stemming from its proposed acquisition of Corange Limited. The consent order permits the acquisition but requires the divestiture of Cardiac thrombolytic agents (drugs used to treat heart attack victims) and ongoing business assets relating to chemicals used to test for the presence of illegal or abused drugs.
FTC Staff Opposes Washington State Proposal to Allow Physician Collective Bargaining
FTC Staff Opposes Alaska Proposal to Allow Physician Collective Bargaining
Displaying 1281 - 1300 of 1535